Lag 3 inhibitors are shaping up as the next big thing. trials have shown that in combination with PD1 inhibitors they improve efficacy alot. That combination efficacy looks like being the new benchmark. Should we get ahead of the curve and have a pd1/lag3/fto inhibitor vs pd1/lag3 trial in the mix? BP is looking at LAG 3 as the next big thing. If you have trials with LAG 3 in the mix it will help zantrene catch the attention of BP and just seems like a good idea. thoughts? somebody float this with Dr T please.
General Comments / Chat, page-5510
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.005(0.34%) |
Mkt cap ! $242.5M | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.50 | $1.43 | $62.91K | 43.17K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5700 | $1.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 591 | 1 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.46 |
Change
-0.005 ( 0.23 %) |
||||
| Open | High | Low | Volume | ||
| $1.44 | $1.49 | $1.43 | 9034 | ||
| Last updated 13.08pm 24/05/2024 ? | |||||
| RAC (ASX) Chart |